Why Gestational Diabetes Hits Pacific Islander Women So Hard

What Was Studied and Why It Matters

Gestational diabetes mellitus (GDM) — high blood sugar that develops during pregnancy — affects women worldwide, but some communities carry a far heavier burden than others. In American Samoa, an estimated 26 to 42 percent of pregnant women develop GDM. That's among the highest rates anywhere on Earth, and yet almost no research has examined why this happens in Pacific Islander populations specifically.

A new study called GROW (Gestational Diabetes — Risk Factors and Outcomes among American Samoan Women) aims to change that. Researchers will follow 350 pregnant women in American Samoa from their first trimester through 18 months after delivery, tracking how blood sugar behaves during and after pregnancy — and why some women go on to develop type 2 diabetes while others do not.

What the Researchers Are Looking For

The GROW study has two major goals:

• Understanding a unique gene: Pacific Islander populations carry a gene variant called CREBRF rs373863828 that appears to protect against type 2 diabetes — yet GDM rates remain extremely high. Researchers want to understand how this gene affects blood sugar control during pregnancy and whether it changes the risk of complications.
• Tracking the full picture of blood sugar: Participants will undergo detailed glucose testing, HbA1c blood tests (which show average blood sugar over several months), and continuous glucose monitoring (CGM) — small wearable sensors that track blood sugar around the clock. They'll also answer questions about diet, sleep, physical activity, and mental health.

What This Means for Real Patients

For women with gestational diabetes — or those at risk — this research matters in very practical ways. GDM doesn't just affect pregnancy. Women who develop it have a significantly higher lifetime risk of type 2 diabetes, and their children may also face metabolic health challenges later in life.

Right now, clinical guidelines for GDM are largely built on research from non-Pacific populations. GROW is designed to fill that gap, potentially leading to screening tools, prevention programs, and treatment approaches that actually fit Pacific Islander women's biology and lived experience.

Continuous glucose monitoring plays a central role in this study — the same technology that many people with diabetes use daily to manage their condition. Reliable CGM supplies and sensors are an important part of ongoing diabetes care, and providers like MDS Diabetes help patients access these tools consistently throughout treatment and monitoring.

What We Don't Know Yet

It's important to note that GROW is a study protocol — a published research plan. Results are not yet available. The findings, when they arrive, are expected to reshape public health guidelines and support precision medicine: matching diabetes prevention strategies to a person's specific genetics and background.

Bottom Line

American Samoan women face gestational diabetes rates that dwarf global averages, yet research into why has been nearly nonexistent. The GROW study is the first major effort to understand this disparity, using advanced blood sugar monitoring and genetic analysis. For Pacific Islander women and their families, this research could eventually lead to better, more personalized diabetes prevention — during pregnancy and beyond.